[{"indications": "Indications\u00a0see notes above", "name": "TRANEXAMIC ACID", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.11 Antifibrinolytic drugs and haemostatics", "TRANEXAMIC ACID"], "cautions": "Cautions\u00a0massive haematuria (avoid if risk of ureteric\r\nobstruction); irregular menstrual bleeding (exclude structural\r\nor histological causes of menorrhagia, or fibroids causing distortion\r\nof the uterine cavity, before initiating treatment);\r\npatients receiving oral contraceptives (increased risk of thrombosis); regular liver function tests in long-term treatment of hereditary\r\nangioedema", "side-effects": "Side-effects\u00a0nausea, vomiting, diarrhoea (reduce dose); rarely disturbances in colour vision (discontinue), thromboembolic\r\nevents, convulsions, allergic skin reactions; dizziness and hypotension\r\non rapid intravenous injection", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2830.htm", "doses": ["By mouth, local fibrinolysis, 1\u20131.5\u00a0g\r\n(or 15\u201325\u00a0mg/kg) 2\u20133 times daily", "Menorrhagia (initiated when menstruation has started), 1\u00a0g 3\r\ntimes daily for up to 4 days; max. 4\u00a0g daily", "Hereditary angioedema, 1\u20131.5\u00a0g 2\u20133 times daily", "Epistaxis, 1\u00a0g 3 times daily for 7 days", "By slow intravenous injection, local fibrinolysis,\r\n0.5\u20131\u00a0g 3 times daily", "By continuous intravenous infusion, local fibrinolysis, following initial treatment by intravenous\r\ninjection, 25\u201350\u00a0mg/kg over 24 hours"], "pregnancy": "Pregnancy\u00a0no evidence of teratogenicity in animal studies; manufacturer advises use only if potential benefit outweighs\r\nrisk\u2014crosses the placenta"}]